uploads/2019/01/Graph-5-11-1.png

Oncology Portfolio: Pfizer’s Key Growth Driver in Fiscal 2018

By

Updated

Oncology portfolio 

In fiscal 2018, Pfizer (PFE) reported oncology product sales of $7.20 billion—a rise of 19% YoY (year-over-year) on a reported and operational basis. Among the revenues, $4.64 billion was earned from the US market—a rise of 6% YoY. International markets contributed the remaining $2.56 billion in revenues—a rise of 53% YoY on a reported basis and 52% on an operational basis.

In the fourth quarter, Pfizer reported oncology product sales of $1.91 billion—a rise of 30% YoY on an operational basis and 27% on a reported basis. Among the revenues, $1.22 billion was earned from the US market, while the remaining $691 million was earned from international markets.

Article continues below advertisement

Ibrance’s growth trends

Pfizer’s leading oncology asset, Ibrance reported revenues of $4.12 billion in fiscal 2018—a rise of 32% YoY on a reported and operational basis. Among the revenues, $2.92 billion was earned from the US market—a rise of 3% YoY. International markets contributed the remaining $1.20 billion of the revenues.

In the fourth quarter, Ibrance reported sales of $1.13 billion—a rise of 62% YoY on an operational basis and 58% on a reported basis. Among the revenues, $743 million was earned from the US market, while the remaining $389 million was earned from international markets.

According to Pfizer’s fourth-quarter earnings conference call, while half of the eligible breast cancer patients in the United States are treated with the combination of CDK inhibitor and endocrine therapy, the remaining patients are treated with chemotherapy or endocrine monotherapy. Pfizer is focused on creating awareness among oncologists about Ibrance’s favorable efficacy and safety profile for these patients.

According to Pfizer’s fourth-quarter earnings conference call, the company wants to maintain Ibrance’s leadership in the CDK4/6 inhibitor class of drugs based on the strength of the clinical data and the favorable real-time experience of more than 100,000 patients who have been prescribed Ibrance.

Next, we’ll discuss Pfizer’s major oncology assets in more detail.

Advertisement

More From Market Realist